$Evaxion(EVAX)$ 默沙东。#Seeking# #biotech#
EVAX announced MSD exercised its option on vaccine candidate EVX-B3 for a $7.5M cash payment, extending Evaxion’s runway into 1H27.
MSD assumes full development costs, with Evaxion eligible for up to $592M in milestones plus royalties. MSD also extended its evaluation period for EVX-B2, with a licensing decision expected 1H26